Over a 3-month period, four patients who had received unrelated donor (UD) bone marrow transplants (BMT) presented with severe mucocutaneous herpes simplex virus (HSV) infection while receiving acyclovir (ACV) prophylaxis. Sensitivity testing of the isolates revealed three to be acyclovir-resistant and in one patient the infection was also characterised by a marked failure to respond to foscarnet (phosphonoformic acid). The emergence of ACV-resistant HSV infections in themselves is a new and challenging problem, and yet a far greater problem will become evident if these infections develop resistance to non thymidine kinase dependent therapy. Keywords: acyclovir-resistant herpes simplex virus infections; bone marrow transplantation Herpes simplex virus (HSV) reactivates in 70-80% of seropositive recipients of allogeneic transplants, causing haemorrhagic mucocutaneous lesions which can add substantially to the morbidity of BMT. These infections are preventable with prophylactic acyclovir (ACV).
Herpes simplex virus (HSV) reactivates in 70-80% of seropositive recipients of allogeneic transplants, causing haemorrhagic mucocutaneous lesions which can add substantially to the morbidity of BMT. These infections are preventable with prophylactic acyclovir (ACV). 1, 2 The mode of action of acyclovir includes phosphorylation by viral thymidine kinase (TK) and then its incorporation into the viral DNA, thus terminating extension of the DNA chain. Resistance is usually due to loss of TK expression (TK−) and a correlation exists between the frequency with which resistant viruses are isolated and the degree of immunosuppression in the host. 3, 4 ACV-resistant HSV infections causing clinical problems in BMT patients have previously been documented, 5 as have resistant herpes virus infections generally. 6 We present a review of four patients who had received unrelated donor bone marrow transplants for the treatment of haematological malignancies and presented over a 3-month period between July and September 1995. They each had serological evidence of previous HSV infection at the time of transplant (complement fixing titres ranging from 24-64) and all four developed recurrent HSV lesions while receiving ACV prophylaxis. The standard regimen for ACV prophylaxis in UD BMT at the time was commenced at day −4 and continued until 6 months post-transplant, but was prolonged in the case of active graft-versus-host disease (GVHD). In patients at risk of cytomegalovirus (CMV) reactivation, the ACV was commenced at 500 mg/m 2 intravenously (i.v.) three times per day until day 30 and then changed to an oral dosage (200 mg five times per day). In those patients not deemed at risk for CMV, ACV was given orally throughout. The implications of the emergence of resistance in this population of immunosuppressed patients will be further discussed.
Case report
Patient A, an 8-year-old girl with biphenotypic leukaemia developed mouth ulcers, culture positive for HSV-1, 5 days post-transplant (isolate A, day +5). She was changed from her oral ACV prophylaxis to high-dose intravenous ACV (10 mg/kg three times daily) for 2 weeks, to which she responded and was then converted back to oral therapy (400 mg × 5/day). However, on developing diarrhoea a week later the mouth ulcers recurred and on this occasion they were successfully treated with a course of foscarnet. The ulcers were again culture positive for HSV-1 but the later isolate was not tested for ACV susceptibility.
Patient B, a 13-year-old female with T cell ALL, developed HSV mouth ulceration from 6 days post-transplant while she was already receiving high-dose i.v. ACV (500 mg/m 2 three times daily) and she was therefore changed to treatment with foscarnet from day +17 to which she responded (isolate B, day +19). After 3 weeks she was converted back to oral ACV (400 mg × 5/day) without further reactivation.
Patient C, a 25-year-old female with AML, first developed HSV-positive mouth ulcers concurrent with the development of GVHD 16 days post-transplant whilst receiving low-dose oral ACV prophylaxis. These ulcers responded to conversion to 5 days of high-dose i.v. ACV therapy (500 mg/m 2 tds). Eight months post-transplant, whilst still on steroid therapy and low-dose oral ACV prophylaxis, she had a further recurrence of HSV mouth ulcers associated with a flare-up of GVHD. She was treated with high-dose i.v. ACV for 3 weeks, but without response on this occasion (isolate C, day +206). During this admission she developed haemolytic uraemic syndrome with cerebral involvement and died shortly after.
Patient D, a 28-year-old male with AML, had prolonged immunosuppression post-transplant with severe GVHD. Six months post-transplant, while continuing on low-dose prophylactic oral ACV, he developed oral HSV lesions which progressed across his face despite high-dose i.v. ACV therapy (isolate D, day +206). On conversion to foscarnet, the facial lesions regressed but did not clear. Due to severe toxicity the foscarnet was stopped after 3 weeks, with concomitant flare-up and progression of the facial lesions through further treatment with ACV and famciclovir. A second course of foscarnet was attempted, on this occasion without clinical response, and was terminated after 10 days because of unacceptable side-effects. Despite ongoing therapy with i.v. ACV and penciclovir he still had spreading HSV-1 culture-positive erosive lesions across his face and left middle finger. Foscarnet was recommenced on day 340 but after 3 weeks there was no clinical response. At the time of his death from bacterial sepsis 12 months post-transplant, he still had clinical HSV disease and at post-mortem there was evidence of both local and disseminated HSV infection.
Laboratory data
Samples from the four patients were inoculated into tubes of vero and human embryo fibroblast cells. On the development of HSV-specific cytopathic effect (CPE) the isolates were typed by direct immunofluorescence using monoclonal antibodies (Syva Microtrak, Milton Keynes, UK): all were found to be HSV-1. Duplicate cultures of each were allowed to progress to complete CPE and the titre of virus in the supernatant of each was measured by plaque assay on vero cells under a methylcellulose overlay. The sensitivity of each strain was determined by a plaque reduction method, incorporating dilutions of ACV (Wellcome, London, UK) into the overlay. SC16, a standard strain 7 of HSV-1 was used as the sensitive control and R16 (a TK− derivative of SC16) as the resistant control. Sensitivities were expressed as the ACV concentration which reduced plaque number by 50% (EP 50 ). The sensitivities (Figure 1 controls were Ͻ0.1 g/ml (SC16) and 1-3.3 g/ml (R16). Those of the clinical isolates were Ͻ0.1 g/ml (isolate A), 1-3.3 g/ml (isolates B and C) and Ͼ10 g/ml (isolate D).
Discussion
These four patients all developed significant HSV infections whilst receiving ACV post-UD BMT and in three cases the isolate tested resistant in vitro. Isolate A proved to be as sensitive in vitro as the sensitive control and the clinical failure of the ACV treatment in this case was probably due to poor absorption of the oral preparation secondary to mucositis and diarrhoea. Isolates B and C showed patterns of resistance similar to that of the resistant control, while isolate D was highly resistant. These results relate closely to the clinical course of the HSV infections in these patients.
ACV resistance usually occurs through the loss of expression of TK but mutants producing less TK, altered TK and altered DNA polymerase have also been reported. The TK− strains have little or no virulence in the immunocompetent, but TK− ACV resistance in clinically apparent HSV infections is more common in all immunocompromised patients. 8 However, the failure of clinical response to foscarnet, as seen in patient D, has previously been described only in HIV-infected individuals: in 26 patients with AIDS an 81% clinical response rate was seen in ACVresistant HSV infection. 9 The difference in degree of resistance found in isolate D in contrast to isolates B and C may reflect different mechanisms of resistance, while the failure of treatment with foscarnet suggests that it is a DNA polymerase mutant. Foscarnet is structurally unrelated to ACV and acts by inhibiting DNA polymerase by binding to its pyrophosphate site. Cross-resistance does not occur with HSV strains having TK-based resistance, but could with DNA polymerase-based resistance involving the pyrophosphate site.
Since immunocompromised patients are susceptible to infection with TK− resistant strains, there is a possibility that in these patients TK− mutants could establish or reestablish latency, with adverse consequences for the treatment of future recurrent disease. It is also possible that transmission to other immunocompromised patients could occur. In mouse models it has been reported that ACV resistant TK− mutants of HSV can produce low levels of TK as a result of a frameshift mechanism and that these are able to reactivate from latency in the mouse trigeminal ganglion. 10 Furthermore, it has also been reported that TK− HSV strains can reactivate in AIDS patients.
11 ACV treatment has been shown to reduce both the numbers of neurones infected and the viral copy number per cell in ganglia after primary HSV infection. 12 TK− mutants generated during ACV treatment of recurrent infections in immunocompromised patients may add to the number of neurones latently infected, so effective alternative treatment of this group of patients may be important in respect of future disease episodes.
The importance of the interaction of immune response with ACV therapy in the recovery from HSV infections as reported by Wade et al 4 is also seen in the cases reported here, although in that study ACV was used intermittently. Patient B developed resistant herpes infection early in the post-transplant period while patients C and D both had GVHD. The commercial availability of other TK-dependent agents such as famciclovir has not solved the problem of ACV resistance and the development of resistance to therapies not TK-dependent is an emergent problem in the transplant population. It is clearly important to have an effective battery of anti-HSV chemotherapeutic agents both to treat current episodes and also to prevent problems with future recurrent disease. The agent (S)-1-[3-hydroxy-2 (phosphonylmethoxy)-propyl] cytosine (HPMPC or cidofovir), which has selective activity against a broad range of DNA viruses including HSV, is an example of an alternative drug which has been reported to be successful in the topical treatment of ACV/foscarnet-resistant HSV infection. 13 It is not TK-dependent but acts directly on the viral DNA polymerase, presumably by binding to other than the pyrophosphate site. The intravenous preparation has recently become licensed and may indeed prove beneficial in such cases as described here, although there is some concern that it may prove to be nephrotoxic if used systemically.
Until the current biological sensitivity tests are replaced by rapid molecular methods, decisions to alter antiviral regimens will be based on clinical criteria, although it should be borne in mind as in case A that clinical failure does not always reflect virological resistance. The authors suggest, therefore, the following clinical strategy. Patients developing HSV lesions while on oral ACV should be changed to high-dose i.v. ACV. If lesions persist after a week or if the patient is already on i.v. ACV, then replacement with foscarnet is advised. If after a further 10 days there is no improvement a trial of cidofovir may be of value. However, there is still an urgent need for more alternative, effective therapies to be developed for the small but growing cohort of patients with ACV-resistant HSV disease.
